Patents Assigned to Pfizer
  • 3-azabicyclo[3.2.1]octane derivatives
    Patent number: 7241887
    Abstract: The subject invention relates to 3-azabicyclo[3.2.1]octane derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by opioid receptors. The subject invention also particularly relates to using such derivatives to treat certain disorders and conditions, for example irritable bowel syndrome, drug addiction, depression, anxiety, schizophrenia and eating disorders, among others.
    Type: Grant
    Filed: April 14, 2004
    Date of Patent: July 10, 2007
    Assignee: Pfizer Inc
    Inventors: Jotham W. Coe, Stanton McHardy, Crystal G. Bashore
  • Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders
    Patent number: 7241786
    Abstract: The present invention relates to compounds of the Formula wherein R1, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, X, Y, Z and n are as defined. Compounds of the Formula I have activity inhibiting production of A?-peptide. This invention also relates to pharmaceutical compositions and methods of treating diseases, for example, neurodegenerative diseases, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: July 10, 2007
    Assignee: Pfizer Inc
    Inventor: Yuhpyng Liang Chen
  • Fluorescence polarization assay
    Publication number: 20070154954
    Abstract: Disclosed are methods and systems that use fluorescence polarization to identify compounds that have the ability to bind to, and/or modulate, the activity of the Receptor for Advanced Glycated Endproducts (RAGE). Compounds identified using the methods and systems of the present invention may comprise small organic molecule RAGE antagonists. The small organic molecule RAGE antagonists identified using the methods and systems of the present invention may be used to treat RAGE-mediated diseases, such as, but not limited to, diabetes or Alzheimer's disease.
    Type: Application
    Filed: March 18, 2005
    Publication date: July 5, 2007
    Applicants: TRANSTECH PHARMA, INC., PFIZER INC.
    Inventors: Adnan Mjalli, Jeffrey Webster
  • Methods for preventing cattle reproductive diseases
    Publication number: 20070154943
    Abstract: The present invention relates to methods for treating or preventing diseases or disorders in a pregnant cow and calf nursing a pregnant cow caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PIV3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a safe modified live viral combination vaccine further combined with a multivalent bacterin vaccine.
    Type: Application
    Filed: March 15, 2007
    Publication date: July 5, 2007
    Applicants: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: Michael Ellsworth, Martin Ficken, Brian Fergen, Cassius Tucker
  • Aryl or heteroaryl amide compounds
    Patent number: 7238714
    Abstract: This invention provides a compound of the formula (I): wherein A represents a phenyl group or the like: B represents an aryl or the like: E represents a 1,4-phenylene group; R1 and R2 independently represent a hydrogen atom or the like: R3 and R4 independently represent a hydrogen atom or the like: R5 represents —CO2H or the like: R6 represents an alkyl group having from 1 to 6 carbon atoms or the like: X represents a methylene group or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: July 3, 2007
    Assignee: Pfizer Japan, Inc.
    Inventors: Kazunari Nakao, Seiji Nukui, Yoshiyuki Okumura, Tatsuya Yamagishi
  • Purine derivatives
    Patent number: 7238676
    Abstract: The present invention relates to compounds of the formula and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as adenosine A2a receptor agonists.
    Type: Grant
    Filed: June 15, 2004
    Date of Patent: July 3, 2007
    Assignee: Pfizer Inc.
    Inventors: Simon John Mantell, Sandra Marina Monaghan, Peter Thomas Stephenson
  • Pyrazole compounds for treatment of neurodegenerative disorders
    Patent number: 7238721
    Abstract: The invention provides compounds of Formula I: wherein R1, R2, R3, R4, R6, R7, R8, and A are as defined. Compounds of formula I have activity inhibiting production of A?-peptide. The invention also provides pharmaceutical compositions and methods for treating diseases, for example Alzheimer's disease, in mammals comprising compounds of Formula I.
    Type: Grant
    Filed: October 7, 2003
    Date of Patent: July 3, 2007
    Assignee: Pfizer Inc
    Inventors: Yuhpyng L. Chen, Spiros Liras, Robert L. Rosati, Martin P. Allen
  • Indole derivatives
    Patent number: 7238723
    Abstract: The present invention provides eletriptan hydrobromide monohydrate of the formula (I): together with processes for preparing, uses of, and compositions containing, said monohydrate.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: July 3, 2007
    Assignee: Pfizer Inc.
    Inventors: Christopher Ian Dallman, Ronald James Ogilvie
  • SUBSTITUTED ARYLPYRAZOLES
    Publication number: 20070149550
    Abstract: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.
    Type: Application
    Filed: December 14, 2006
    Publication date: June 28, 2007
    Applicant: PFIZER INC.
    Inventors: Denis Billen, Jessica Boyle, Douglas Critcher, David Gethin, Kim Hall, Graham Kyne
  • Combination Therapy
    Publication number: 20070149578
    Abstract: This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and statins or pharmaceutically acceptable salts thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and statins or pharmaceutically acceptable salts thereof whereby those additive and synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.
    Type: Application
    Filed: October 16, 2006
    Publication date: June 28, 2007
    Applicant: Pfizer, Inc.
    Inventors: Jan Buch, Robert Scott
  • ESTROGEN MODULATORS
    Publication number: 20070149564
    Abstract: The present application is directed to a new class of isoxazoles and their use as estrogen modulators.
    Type: Application
    Filed: December 19, 2006
    Publication date: June 28, 2007
    Applicant: PFIZER INC.
    Inventors: Simon Bailey, Stephen Barrett, Larry Bratton, Stephen Fakhoury, Sandra Jennings, Lorna Mitchell, Raj Raheja, Veerabahu Shanmugasundaram
  • COMBINATION
    Publication number: 20070149464
    Abstract: Compounds of formula (I) are used in combination with a second antiparasitic agent for the treatment of parasitic infestations in a host animal.
    Type: Application
    Filed: December 14, 2006
    Publication date: June 28, 2007
    Applicant: PFIZER INC.
    Inventors: Denis Billen, Jessica Boyle, Douglas Critcher, David Gethin, Kim Hall, Graham Kyne
  • Quinoline compounds
    Publication number: 20070149567
    Abstract: Quinoline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDLcholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
    Type: Application
    Filed: September 12, 2005
    Publication date: June 28, 2007
    Applicant: Pfizer Inc
    Inventors: Mary Didiuk, Ryan Kelley, David Perry, Roger Ruggeri
  • Benzamide, heteroarylamide and reverse amides
    Patent number: 7235549
    Abstract: The present invention relates to novel to P2X7 inhibitors of formula I and to processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in therapy. The active compounds of the present invention are potent inhibitors of P2X7 and as such are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    Type: Grant
    Filed: October 18, 2005
    Date of Patent: June 26, 2007
    Assignee: Pfizer Inc.
    Inventors: Allen J. Duplantier, Chakrapani Subramanyam
  • Pyrimidine derivatives for the treatment of abnormal cell growth
    Patent number: 7235562
    Abstract: The present invention relates to a compound of the formula 1 wherein R1-R4 and Ar are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: June 26, 2007
    Assignee: Pfizer Inc
    Inventors: John Charles Kath, Michael Joseph Luzzio
  • Pharmaceutical compositions of a sparingly soluble glycogen phosphorylase inhibitor
    Patent number: 7235260
    Abstract: Pharmaceutical compositions of a particularly effective sparingly soluble glycogen phosphorylase inhibitor are disclosed, as well as methods of making such compositions and dosage forms from such compositions.
    Type: Grant
    Filed: March 21, 2003
    Date of Patent: June 26, 2007
    Assignee: Pfizer Inc
    Inventors: Marshall D. Crew, Dwayne T. Friesen, Bruno C. Hancock, Chris Macri, James A. S. Nightingale, Ravi M. Shankar
  • Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
    Patent number: 7235259
    Abstract: A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: June 26, 2007
    Assignee: Pfizer Inc
    Inventors: Marshall D. Crew, William J. Curatolo, Dwayne T. Friesen, Michael Jon Gumkowski, Douglas A. Lorenz, James A. S. Nightingale, Roger B. Ruggeri, Ravi M. Shanker
  • Methods for preparing P2X inhibitors
    Patent number: 7235657
    Abstract: The present invention relates to the methods for preparing compounds of the formula I: or the pharmaceutically acceptable salts thereof, wherein R1, R2, R4, R10, and R11 have any of the values defined in the specification. The compounds of the present invention are useful in the treatment of diseases, including inflammatory diseases such as rheumatoid arthritis.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: June 26, 2007
    Assignee: Pfizer Inc.
    Inventor: Zhengong Bryan Li
  • PIPERIDINE DERIVATIVES
    Publication number: 20070142389
    Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein R6 and R10 have any of the values defined therefor in the specification; pharmaceutical compositions; methods of treating conditions, diseases, and disorders; and therapeutic combinations.
    Type: Application
    Filed: December 14, 2006
    Publication date: June 21, 2007
    Applicant: PFIZER INC.
    Inventors: Michelle Bruendl, Keri Greene, Rex Jennings, Scott Lazerwith, Joe Nahra, Patrick O'Brien, Kimberly Para, Susan Sheehan
  • Substituted pyrazolo[4,3-e]diazepines, pharmaceutical compositions containing them, use as medical products and processes for preparing them
    Patent number: 7232816
    Abstract: The invention relates to novel substituted pyrazolo[4,3-e]-diazepines of general formula: to pharmaceutical compositions containing them, to their use as medicinal products and to processes for preparing them.
    Type: Grant
    Filed: February 2, 2005
    Date of Patent: June 19, 2007
    Assignee: Pfizer, Inc.
    Inventors: Catherine Burnouf, Amaya Berecibar, Michael Navet